Acceleron Pharma Inc. (XLRN)

44.57
NASDAQ : Health Technology
Prev Close 43.28
Day Low/High 43.15 / 45.45
52 Wk Low/High 37.01 / 58.11
Avg Volume 278.50K
Exchange NASDAQ
Shares Outstanding 53.08M
Market Cap 2.30B
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Acceleron Pharma Reports Fourth Quarter And Year Ended 2015 Financial And Operational Results And Recent Highlights

Acceleron Pharma Reports Fourth Quarter And Year Ended 2015 Financial And Operational Results And Recent Highlights

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

19 Charts to Calm Your Recession Fears

19 Charts to Calm Your Recession Fears

Is it better to choose stocks through fundamental or technical analysis? Real Money's Bruce Kamich puts his technical spin on these recession-proof stocks chosen by Morgan Stanley analysts.

Acceleron Pharma To Host Fourth Quarter And Year Ended 2015 Financial Results

Acceleron Pharma To Host Fourth Quarter And Year Ended 2015 Financial Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

19 Stocks You Should Own if the U.S. Falls Into a Recession

19 Stocks You Should Own if the U.S. Falls Into a Recession

As speculation mounts that the U.S. economy will enter a recession, here are 19 stocks you should own just in case.

Acceleron Pharma Enters Oversold Territory (XLRN)

Acceleron Pharma Enters Oversold Territory (XLRN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Acceleron Pharma To Participate In Two Healthcare Investor Conferences In February

Acceleron Pharma To Participate In Two Healthcare Investor Conferences In February

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

5 Stocks to Trade for Breakout Gains

5 Stocks to Trade for Breakout Gains

These stocks look ready to break out and trade higher from current levels.

Insider Trading Alert - XLRN, TTMI And AGX Traded By Insiders

Insider Trading Alert - XLRN, TTMI And AGX Traded By Insiders

Stocks with insider trader activity include XLRN, TTMI and AGX

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

I'm only making one big prediction this year: The five-year party which saw biotech stocks outperform the broader markets comes to an end in 2016.

Acceleron Pharma (XLRN) Trading With Heavy Volume Before Market Open

Acceleron Pharma (XLRN) Trading With Heavy Volume Before Market Open

Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a pre-market mover with heavy volume candidate

Acceleron Announces Pricing Of Public Offering Of Common Stock

Acceleron Announces Pricing Of Public Offering Of Common Stock

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Acceleron Announces Proposed Public Offering Of Common Stock

Acceleron Announces Proposed Public Offering Of Common Stock

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Celgene And Acceleron Announce New Results From An Investigational Study With Luspatercept In Beta-Thalassemia Presented At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition

Celgene And Acceleron Announce New Results From An Investigational Study With Luspatercept In Beta-Thalassemia Presented At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition

Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced preliminary results from two Phase 2 clinical trials of luspatercept in patients with beta-thalassemia were presented at the 57 th...

FDA Fast Track Designation Granted To Luspatercept For The Treatment Of Patients With Lower-Risk Myelodysplastic Syndromes

FDA Fast Track Designation Granted To Luspatercept For The Treatment Of Patients With Lower-Risk Myelodysplastic Syndromes

Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to luspatercept for the treatment of...

Investors Remain Skeptical about Bluebird Gene Therapy for Blood Disease

Investors Remain Skeptical about Bluebird Gene Therapy for Blood Disease

Bluebird Bio is going to have a rough Monday because of the disappointing gene therapy data presented over the weekend at the American Society of Hematology annual meeting.

Celgene And Acceleron Announce New Results From An Investigational Study With Luspatercept In Myelodysplastic Syndromes Presented At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition

Celgene And Acceleron Announce New Results From An Investigational Study With Luspatercept In Myelodysplastic Syndromes Presented At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition

Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced preliminary results from an ongoing long-term Phase 2 extension study in patients with lower risk myelodysplastic syndromes (MDS) at...

Acceleron Announces Oral Plenary Presentation For ACE-083 In The Late Breaking Clinical Trials Session At The 8th International Conference On Cachexia, Sarcopenia And Muscle Wasting

Acceleron Announces Oral Plenary Presentation For ACE-083 In The Late Breaking Clinical Trials Session At The 8th International Conference On Cachexia, Sarcopenia And Muscle Wasting

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, announced...

Acceleron Pharma To Present At Piper Jaffray 27th Annual Healthcare Conference

Acceleron Pharma To Present At Piper Jaffray 27th Annual Healthcare Conference

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Acceleron Announces New Data Presentations At The 2015 American Society Of Hematology Annual Meeting

Acceleron Announces New Data Presentations At The 2015 American Society Of Hematology Annual Meeting

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Acceleron Pharma Reports Third Quarter 2015 Financial And Operational Results

Acceleron Pharma Reports Third Quarter 2015 Financial And Operational Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Acceleron Pharma To Present At Upcoming Investor Conferences In November

Acceleron Pharma To Present At Upcoming Investor Conferences In November

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Acceleron Pharma To Host Third Quarter 2015 Financial Results Conference Call And Webcast On November 4, 2015

Acceleron Pharma To Host Third Quarter 2015 Financial Results Conference Call And Webcast On November 4, 2015

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Acceleron Highlights Phase 3 Studies, New Clinical Results And Research Strategies At Research And Development Day Event

Acceleron Highlights Phase 3 Studies, New Clinical Results And Research Strategies At Research And Development Day Event

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Acceleron To Host Research And Development Day On October 23

Acceleron To Host Research And Development Day On October 23

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Commit To Buy Acceleron Pharma At $20, Earn 24% Annualized Using Options

Commit To Buy Acceleron Pharma At $20, Earn 24% Annualized Using Options

Investors eyeing a purchase of Acceleron Pharma, Inc. shares, but cautious about paying the going market price of $24.01/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Acceleron Announces Presentation Of Sotatercept Data At The American Society Of Nephrology Kidney Week 2015

Acceleron Announces Presentation Of Sotatercept Data At The American Society Of Nephrology Kidney Week 2015

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Acceleron Presents Preclinical Data For ACE-083 And ACE-2494 At The 20th International Annual Congress Of The World Muscle Society

Acceleron Presents Preclinical Data For ACE-083 And ACE-2494 At The 20th International Annual Congress Of The World Muscle Society

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Trade-Ideas: Acceleron Pharma (XLRN) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Acceleron Pharma (XLRN) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a weak on high relative volume candidate

Acceleron Pharma To Present At Upcoming Investor Conferences In September

Acceleron Pharma To Present At Upcoming Investor Conferences In September

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Acceleron Pharma (XLRN) Highlighted As Weak On High Volume

Acceleron Pharma (XLRN) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a weak on high relative volume candidate

TheStreet Quant Rating: D+ (Sell)